GlobeNewswire
Contact Us
Register
Sign In
English
Français
About this file
Figure 1
Figure 1
Akari Therapeutics Plc
Format
JPEG
Source
Akari Therapeutics Plc
Downloads
Original
Large
Medium
Small
ASSOCIATED PRESS RELEASE
Akari Therapeutics Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients with Bullous Pemphigoid, Highlighting Potential Advantages of Coversin’s bifunctional activity inhibiting both the Complement and Leukotriene Inflammatory Pathways
Published
September 12, 2018 07:00 ET